TIDMAZN
RNS Number : 7141E
AstraZeneca PLC
03 July 2023
This announcement contains inside information
3 July 2023
Datopotamab deruxtecan met dual primary endpoint of
progression-free survival in patients with advanced
non-small cell lung cancer in TROPION-Lung01 Phase III trial
First Phase III results for AstraZeneca and Daiichi Sankyo's
TROP2-directed antibody drug conjugate demonstrated statistically
significant
improvement in progression-free survival vs. standard
chemotherapy
in previously treated locally advanced or metastatic disease
Trial will continue to assess the dual primary endpoint of
overall survival
Positive high-level results from the TROPION-Lung01 Phase III
trial showed datopotamab deruxtecan (Dato-DXd) demonstrated a
statistically significant improvement for the dual primary endpoint
of progression-free survival (PFS) compared to docetaxel, the
current standard of care chemotherapy, in patients with locally
advanced or metastatic non-small cell lung cancer (NSCLC) treated
with at least one prior therapy.
For the dual primary endpoint of overall survival (OS), the data
were not mature and an early trend was observed in favour of
datopotamab deruxtecan versus docetaxel that did not meet the
prespecified threshold for statistical significance at this interim
analysis. The trial will continue as planned to assess OS with
greater maturity. The investigators and participants will remain
blinded to the results.
The safety profile of datopotamab deruxtecan was consistent with
previous clinical trials with no new safety signals identified. All
grade interstitial lung disease was generally consistent with prior
clinical trials, with the majority being low grade. Some Grade 5
events were observed.
Datopotamab deruxtecan is a specifically engineered
TROP2-directed DXd antibody drug conjugate (ADC) being jointly
developed by AstraZeneca and Daiichi Sankyo.
Susan Galbraith, Executive Vice President, Oncology R&D,
AstraZeneca, said: " With TROPION-Lung01, we met the dual primary
endpoint of progression-free survival, challenging the entrenched
standard of care in a previously treated and unselected patient
population that has long deserved an alternative to chemotherapy.
These first Phase III trial results from the datopotamab deruxtecan
clinical programme provide compelling evidence for the potential
role this TROP2-directed antibody drug conjugate can play in
treating patients with lung cancer."
Ken Takeshita, MD, Global Head, Oncology R&D, Daiichi
Sankyo, said: "We are encouraged by the statistically significant
results of the dual primary endpoint of progression-free survival
seen with datopotamab deruxtecan and look forward to the final
overall survival analysis. We plan to share these data with
regulatory authorities to discuss next steps."
More than one million people worldwide are diagnosed with
advanced NSCLC each year.(1,2) While immunotherapy and targeted
therapies have improved outcomes in the 1st-line metastatic
setting, most patients eventually experience disease progression
and receive chemotherapy.(3-5) For decades, chemotherapy has been
the last treatment available for patients with advanced NSCLC in
the absence of other treatment options and despite limited
effectiveness and known side effects.(3-5) TROP2 is a protein
highly expressed in a large majority of lung cancers. There are
currently no TROP2-directed ADCs approved for the treatment of
patients with lung cancer.(6-8)
TROPION-Lung01 enrolled patients with and without actionable
genomic alterations, such as EGFR and ALK. Patients with actionable
genomic alterations were previously treated with platinum-based
chemotherapy and an approved targeted therapy. Patients without
actionable genomic alterations were previously treated,
concurrently or sequentially, with platinum-based chemotherapy and
a PD-1 or PD-L1 inhibitor.
The data will be presented at a forthcoming medical meeting and
shared with health authorities.
Notes
Non-small cell lung cancer
More than one million people worldwide are diagnosed with
advanced NSCLC each year.(1,2) While immunotherapy and targeted
therapies have improved outcomes in the 1st-line metastatic
setting, most patients eventually experience disease progression
and receive chemotherapy.(3-5) For decades, chemotherapy has been
the last treatment available for patients with advanced NSCLC in
the absence of other treatment options and despite limited
effectiveness and known side effects.(3-5)
TROP2 is a protein highly expressed in a large majority of lung
cancers. (6) There are currently no TROP2-directed ADCs approved
for the treatment of patients with lung cancer.(7,8)
TROPION-Lung01
TROPION-Lung01 is a global, randomised, multicentre, open-label
Phase III trial evaluating the efficacy and safety of datopotamab
deruxtecan (6.0 mg/kg) versus docetaxel (75 mg/m(2) ) in patients
with locally advanced or metastatic NSCLC, with or without
actionable genomic alterations, treated with at l east one prior
therapy. Patients without actionable genomic alterations were
previously treated, concurrently or sequentially, with
platinum-based chemotherapy and a prior PD-1 or PD-L1 inhibitor.
Patients with actionable genomic alterations were previously
treated with platinum-based chemotherapy and targeted therapy as
approved for their detected genomic alteration.
The dual primary endpoints of TROPION-Lung01 are PFS as assessed
by blinded independent central review (BICR) and OS. Key secondary
endpoints include investigator-assessed PFS, objective response
rate, duration of response, time to response and disease control
rate as assessed by both BICR and an investigator, and safety.
TROPION-Lung01 enrolled approximately 600 patients at sites in
Asia, Europe, North America and South America. For more information
visit ClinicalTrials.gov .
Datopotamab deruxtecan (Dato-DXd)
Datopotamab deruxtecan (Dato-DXd) is an investigational
TROP2-directed ADC. Designed using Daiichi Sankyo's proprietary DXd
ADC technology, datopotamab deruxtecan is one of five lead ADCs in
the oncology pipeline of Daiichi Sankyo, and one of the most
advanced programmes in AstraZeneca's ADC scientific platform.
Datopotamab deruxtecan is comprised of a humanized anti-TROP2 IgG1
monoclonal antibody, developed in collaboration with Sapporo
Medical University, attached to a number of topoisomerase I
inhibitor payloads, an exatecan derivative, via tetrapeptide-based
cleavable linkers.
A comprehensive development programme is underway globally with
more than 12 trials evaluating the efficacy and safety of
datopotamab deruxtecan across multiple TROP2-targetable tumours,
including NSCLC, triple-negative breast cancer and hormone
receptor-positive, HER2-low or negative breast cancer. Beyond the
TROPION programme, datopotamab deruxtecan is also being evaluated
in novel combinations in several ongoing trials.
In NSCLC, the TROPION-Lung07, TROPION-Lung08 and AVANZAR Phase
III trials are evaluating datopotamab deruxtecan and immune
checkpoint inhibitor combinations as potential 1st-line treatment
options for patients with advanced or metastatic disease, a
strategy informed by the results of two early trials. AstraZeneca
is also researching a potential diagnostic test to help identify
patients most likely to benefit from treatment with datopotamab
deruxtecan.
AstraZeneca and Daiichi Sankyo collaboration
AstraZeneca and Daiichi Sankyo entered into a global
collaboration to jointly develop and commercialise Enhertu in March
2019 and datopotamab deruxtecan in July 2020 , except in Japan
where Daiichi Sankyo maintains exclusive rights for each ADC.
Daiichi Sankyo is responsible for the manufacturing and supply of
Enhertu and datopotamab deruxtecan.
AstraZeneca in lung cancer
AstraZeneca is working to bring patients with lung cancer closer
to cure through the detection and treatment of early-stage disease,
while also pushing the boundaries of science to improve outcomes in
the resistant and advanced settings. By defining new therapeutic
targets and investigating innovative approaches, the Company aims
to match medicines to the patients who can benefit most.
The Company's comprehensive portfolio includes leading lung
cancer medicines and the next wave of innovations, including
Tagrisso (osimertinib) and Iressa (gefitinib); Imfinzi (durvalumab)
and Imjudo (tremelimumab); Enhertu (trastuzumab deruxtecan) and
datopotamab deruxtecan in collaboration with Daiichi Sankyo;
Orpathys (savolitinib) in collaboration with HUTCHMED; as well as a
pipeline of potential new medicines and combinations across diverse
mechanisms of action.
AstraZeneca is a founding member of the Lung Ambition Alliance,
a global coalition working to accelerate innovation and deliver
meaningful improvements for people with lung cancer, including and
beyond treatment.
AstraZeneca in oncology
AstraZeneca is leading a revolution in oncology with the
ambition to provide cures for cancer in every form, following the
science to understand cancer and all its complexities to discover,
develop and deliver life-changing medicines to patients.
The Company's focus is on some of the most challenging cancers.
It is through persistent innovation that AstraZeneca has built one
of the most diverse portfolios and pipelines in the industry, with
the potential to catalyse changes in the practice of medicine and
transform the patient experience.
AstraZeneca has the vision to redefine cancer care and, one day,
eliminate cancer as a cause of death.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries and its innovative medicines are used by millions of
patients worldwide. Please visit astrazeneca.com and follow the
Company on Twitter @ AstraZeneca .
Contacts
For details on how to contact the Investor Relations Team,
please click here . For Media contacts, click here .
References
1. Siegel R, et al. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71:7-33.
2. World Health Organization. International Agency for Research
on Cancer. Lung Fact Sheet. Available at:
https://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf
. Accessed July 2023.
3. Chen R, et al. Emerging therapeutic agents for advanced
non-small cell lung cancer. J Hematol Oncol. 2020;13(1):58.
4. Majeed U, et al. Targeted therapy in advanced non-small cell
lung cancer: current advances and future trends. J Hematol Oncol.
2021;14(1):108.
5. Pircher, A, et al. Docetaxel in the Treatment of Non-small
Cell Lung Cancer (NSCLC) - An Observational Study Focusing on
Symptom Improvement. Anticancer Research. 2013;33(9):3831-3836.
6. Mito R, et al. Clinical impact of TROP2 in non -- small lung
cancers and its correlation with abnormal p53 nuclear accumulation.
Pathol Int. 2020;70(5):287-294.
7. Rodríguez-Abreau D et al. Pemetrexed plus platinum with or
without pembrolizumab in patients with previously untreated
metastatic nonsquamous NSCLC: protocol-specified final analysis
from KEYNOTE-189. Ann Onc. 2021 Jul;32(7): 881-895.
8. American Cancer Society. Targeted Drug Therapy for Non-Small Cell Lung Cancer. Available at: https://www.cancer.org/cancer/types/lung-cancer/treating-non-small-cell/targeted-therapies.html. Accessed July 2023.
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCEXLBBXDLLBBB
(END) Dow Jones Newswires
July 03, 2023 02:00 ET (06:00 GMT)
Astrazeneca (LSE:0A4J)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Astrazeneca (LSE:0A4J)
Historical Stock Chart
Von Mai 2023 bis Mai 2024